［1］ SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73(1):17-48.
［2］ LI T,ZHOU S,YANG Y,et al.LncRNA Mnx1-As1:A novel oncogenic propellant in cancers［J］.Biomed Pharmacother,2022,149:112801.
［3］ TAN YT,LIN JF,LI T,et al.LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer［J］.Cancer Commun (Lond),2021,41(2):109-120.
［4］ PENG WX,KOIRALA P,MO YY.LncRNA-mediated regulation of cell signaling in cancer［J］.Oncogene,2017,36(41):5661-5667.
［5］ MCCABE EM,RASMUSSEN TP.LncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions［J］.Semin Cancer Biol,2021,75:38-48.
［6］ FENG YC,LIU XY,TENG L,et al.C-Myc inactivation of p53 through the pan-cancer LncRNA Milip drives cancer pathogenesis［J］.Nat Commun,2020,11(1):4980.
［7］ FENG YC,ZHAO XH,TENG L,et al.The pan-cancer LncRNA Milip links C-Myc to p53 repression［J］.Mol Cell Oncol,2020,8(1):1842714.
［8］ TAN AC,TAN DSW.Targeted therapies for lung cancer patients with oncogenic driver molecular alterations［J］.J Clin Oncol,2022,40(6):611-625.
［9］ OLIVER AL.Lung cancer:Epidemiology and screening［J］.Surg Clin North Am,2022,102(3):335-344.
［10］ LI W,LIU JB,HOU LK,et al.Liquid biopsy in lung cancer:Significance in diagnostics,prediction,and treatment monitoring［J］.Mol Cancer,2022,21(1):25.
［11］ WU Q,JIANG J.LncRNA Mafg-As1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-3196 and regulating Sox12 expression［J］.Mol Biotechnol,2022,64(9):970-983.
［12］ JIA YC,WANG JY,LIU YY,et al.LncRNA Mafg-As1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from Mmp15［J］.Cell Biol Int,2019,43(4):384-393.
［13］ WILKINSON L,GATHANI T.Understanding breast cancer as a global health concern［J］.Br J Radiol,2022,95(1130):20211033.
［14］ KASHYAP D,PAL D,SHARMA R,et al.Global increase in breast cancer incidence:risk factors and preventive measures［J］.Biomed Res Int,2022,2022:9605439.
［15］ SAATCI O,HUYNH-DAM KT,SAHIN O.Endocrine resistance in breast cancer:from molecular mechanisms to therapeutic strategies［J］.J Mol Med (Berl),2021,99(12):1691-1710.
［16］ NASSIF AB,TALIB MA,NASIR Q,et al.Breast cancer detection using artificial intelligence techniques:a systematic literature review［J］.Artif Intell Med,2022,127:102276.
［17］ DI S,BAI R,LU D,et al.Long non-coding RNA Mafg-As1 promotes proliferation and metastasis of breast cancer by modulating Stc2 pathway［J］.Cell Death Discov,2022,8(1):249.
［18］ DAI J,ZHANG S,SUN H,et al.LncRNA Mafg-As1 affects the tumorigenesis of breast cancer cells via the miR-574-5p/Sod2 axis［J］.Biochem Biophys Res Commun,2021,560:119-125.
［19］ FENG J,WEN T,LI Z,et al.Cross-Talk between the ER pathway and the LncRNA Mafg-As1/miR-339-5p/Cdk2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance［J］.Aging(Albany NY),2020,12(20):20658-20683.
［20］ VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma［J］.Lancet,2022,400(10360):1345-1362.
［21］ HU ZQ,LI HC,TENG F,et al.Long noncoding RNA Mafg-As1 facilitates the progression of hepatocellular carcinoma via targeting miR-3196/Otx1 axis［J］.Eur Rev Med Pharmacol Sci,2020,24(23):12131-12143.
［22］ ZHANG F,LI Y,GAN L,et al.Hbx-upregulated Mafg-As1 promotes cell proliferation and migration of hepatoma cells by enhancing Mafg expression and stabilizing nonmuscle myosin Iia［J］.Faseb J,2021,35(5):e21529.
［23］ TIAN Y,WANG J,TIAN G,et al.Long non-coding RNA Mafg-As1 as a potential biomarker for hepatocellular carcinoma:linkage with tumor features,markers,liver functions,and survival profile［J］.Front Surg,2022,9:848831.
［24］ COMPERAT E,AMIN MB,CATHOMAS R,et al.Current best practice for bladder cancer:a narrative review of diagnostics and treatments［J］.Lancet,2022,400(10364):1712-1721.
［25］ LI D,ZHONG S,ZHU Z,et al.LncRNA Mafg-As1 promotes the progression of bladder cancer by targeting the miR-143-3p/Cox-2 axis［J］.Pathobiology,2020,87(6):345-355.
［26］ XIAO M,LIU J,XIANG L,et al.Mafg-As1 promotes tumor progression via regulation of the Hur/Ptbp1 axis in bladder urothelial carcinoma［J］.Clin Transl Med,2020,10(8):e241.
［27］ FU Y,WEN J,LI X,et al.LncRNA Mafg-As1 upregulates Polo-Like Kinase-1 by sponging miR-505 to promote gastric adenocarcinoma cell proliferation［J］.Crit Rev Eukaryot Gene Expr,2021,31(5):27-32.
［28］ QIAN CJ,XU ZR,CHEN LY,et al.LncRNA Mafg-As1 accelerates cell migration,invasion and aerobic glycolysis of esophageal squamous cell carcinoma cells via miR-765/Pdx1 axis［J］.Cancer Manag Res,2020,12:6895-6908.
［29］ WANG Y,FENG YC,GAN Y,et al.LncRNA Milip links Ybx1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma［J］.J Exp Clin Cancer Res,2022,41(1):260.
［30］ ZHAO H,LI J,YAN X,et al.LncRNA Mafg-As1 suppresses the maturation of miR-34a to promote glioblastoma cell proliferation［J］.Cancer Manag Res,2021,13:3493-3501.
［31］ YE L,FENG W,WENG H,et al.Mafg-As1 aggravates the progression of pancreatic cancer by sponging miR-3196 to boost Nfix［J］.Cancer Cell Int,2020,20(1):591.
［32］ BAI Y,REN C,WANG B,et al.LncRNA Mafg-As1 promotes the malignant phenotype of ovarian cancer by upregulating Nfkb1-dependent Igf1［J］.Cancer Gene Ther,2022,29(3-4):277-291.
［33］ WANG PL,TENG L,FENG YC,et al.The N-Myc-responsive LncRNA Milip promotes DNA double-strand break repair through non-homologous end joining［J］.Proc Natl Acad Sci USA,2022,119(49):e2208904119.
［34］ SUI Y,LIN G,ZHENG Y,et al.LncRNA Mafg-As1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/Mafg axis［J］.Eur J Pharmacol,2019,859:172465.
［35］ GAO Z,ZHENG G,GONG X,et al.LncRNA Mafg-As1 deregulated in breast cancer affects autophagy and progression of breast cancer by interacting with miR-3612 and Fkbp4 invitro［J］.Biochem Biophys Res Commun,2022,616:95-103.
［36］ JIA H,WU D,ZHANG Z,et al.Regulatory effect of the Mafg-As1/miR-150-5p/Myb axis on the proliferation and migration of breast cancer cells［J］.Int J Oncol,2021,58(1):33-44.
［37］ DING M,FU Y,GUO F,et al.Long non-coding RNA Mafg-As1 knockdown blocks malignant progression in breast cancer cells by inactivating Jak2/Stat3 signaling pathway via Mafg-As1/miR-3196/Tfap2a axis［J］.Int J Clin Exp Pathol,2020,13(10):2455-2473.
［38］ LI H,ZHANG GY,PAN CH,et al.LncRNA Mafg-As1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/Mmp15［J］.Eur Rev Med Pharmacol Sci,2019,23(7):2838-2846.
［39］ TANG C,WU Y,WANG X,et al.LncRNA Mafg-As1 regulates miR-125b-5p/Sphk1 axis to promote the proliferation,migration,and invasion of bladder cancer cells［J］.Hum Cell,2021,34(2):588-597.
［40］ SUN X,CAI Y,HU X,et al.Long noncoding RNA Mafg-As1 facilitates bladder cancer tumorigenesis via regulation of miR-143-3p/Serpine1 axis［J］.Transl Cancer Res,2020,9(11):7214-7226.
［41］ OUYANG H,ZHANG L,XIE Z,et al.Long noncoding RNA Mafg-As1 promotes proliferation,migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852［J］.Exp Ther Med,2019,18(4):2547-2553.
［42］ CHEN T,HUANG B,PAN Y.Long non-coding RNA Mafg-As1 promotes cell proliferation,migration,and Emt by miR-3196/Strn4 in drug-resistant cells of liver cancer［J］.Front Cell Dev Biol,2021,9:688603.
［43］ WINKLE M,EL-DALY SM,FABBRI M,et al.Noncoding RNA therapeutics-challenges and potential solutions［J］.Nat Rev Drug Discov,2021,20(8):629-651.